Coronavirus Response

 

The World Health Organization has declared the ongoing COVID-19 outbreak, caused by the virus SARS-CoV-2, a global pandemic. The IPD is focused on seven research projects that we hope will have an immediate impact:

Antiviral and anti-inflammatory proteins

Hyperstable binding proteins are being designed to target the SARS-CoV-2 spike glycoprotein, the human ACE-2 receptor, and receptors implicated in cytokine storms.

ANTIVIRAL PROTEIN BLOCK SARS-COV-2  | CAO ET AL, 2020

Protease inhibitors

A new generation of protease inhibitors made from structured macrocycles with non-canonical residues are being designed to stop SARS-CoV-2 proteases.

MACROCYCLE DESIGN  | HOSSEINZADEH ET AL, 201

Screening existing drugs 

Over 8,000 FDA-approved compounds are being screened in silico for binding to structures from the SARS-CoV-2 proteome.

Modeling the viral proteome

Rosetta is being used to model the 3D structures of important proteins from the SARS-CoV-2 coronavirus. 

VIEW MODELS

Nanoparticle vaccines 

Using technology created at the IPD, an array of candidate COVID-19 vaccines has been designed, characterized, and fast-tracked into animal testing. 

RSV NANOPARTICLE VACCINE  | WALLS, FIALA ET AL, 2020

Serological diagnostics 

LOCKR technology is being reconfigured into a sensitive in-solution serological assay to rapidly detect SARS-CoV-2 antibodies in body fluid samples.

LOCKR 101  | COVID-19 DIAGNOSTIC PRE-PRINT

Nanoparticles to treat inflammation

New methods for controlling cell signaling are being applied to create new nanoparticle super-agonists for regenerative medicine.

DESIGNER LIGANDS  | MOHAN ET AL, 2019

Citizen science

We are empowering everyone to join the fight against COVID-19 through Foldit and Rosetta@Home. Foldit player’s solutions to our new coronavirus puzzles are being manufactured and tested in the lab. 

FOLDIT  | ROSETTA@HOME

 

Join us


The IPD’s ability to meet the demands of the COVID-19 challenge is in part due to early supporters, leadership funding from the Bill & Melinda Gates Foundation, and the recent, transformative investment from The Audacious Project. Today, visionary philanthropists can help provide the resources to continue advancing our COVID-19 response. 

If you would like to make a gift to support the Institute for Protein Design, please contact Katherine Cardinal, senior director for philanthropy, at 206.650.4503 or cardinal@uw.edu, Damien Chapman, director for corporate and foundation relations, at 206.616.4483 or damienc@uw.edu, or Lance Stewart, chief strategy and operations officer, at 206.383.4187 or ljs5@uw.edu.

Thank you for your interest in the institute’s work.


“This outbreak has illustrated that it’s all hands on deck, and all of us together against the bugs. We are working with our collaborators at UW, the NIH, and the Bill & Melinda Gates Foundation to help create a safe and effective vaccine for not only SARS-CoV-2 but other coronaviruses as well.” Neil King, head of vaccine design at the IPD


News